AR Degrader-2
AR Degrader-2 is a bifunctional androgen receptor degrader that is applicable to cancer-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3023359-76-1
- Formule: C40H49ClN6O4
- Masse moléculaire:713.31
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
In Vitro
AR Degrader-2 (Compound 2) mediates AR protein degradation in VCaP cells, with a measured DC50 ≥ 300 nM and < 500 nM, and a Dmax > 50 % and < 65 %[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 3023359-76-1
-
Masse moléculaire 713.31
-
Formule C40H49ClN6O4
-
SMILES
CC(C)([C@H](C1(C)C)NC(C2=CC=C(N3CCC(CC3)C(N4CCN(CC4)C(/C(C#N)=C/C(C)(C)C)=O)=O)C=C2)=O)[C@H]1OC5=CC(Cl)=C(C=C5)C#N
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)